Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2019 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.
Lê MP, Chaix ML, Raffi F, Chevret S, Gallien S, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS-165 DARULIGHT study group. Lê MP, et al. Br J Clin Pharmacol. 2019 Jan;85(1):277-280. doi: 10.1111/bcp.13796. Epub 2018 Nov 12. Br J Clin Pharmacol. 2019. PMID: 30421447 Free PMC article. Clinical Trial. No abstract available.
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
Lê MP, Chaix ML, Chevret S, Bertrand J, Raffi F, Gallien S, El Abbassi EMB, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS 165 DARULIGHT Study Group. Lê MP, et al. J Antimicrob Chemother. 2018 Aug 1;73(8):2120-2128. doi: 10.1093/jac/dky193. J Antimicrob Chemother. 2018. PMID: 29905808 Clinical Trial.
Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight).
Molina JM, Gallien S, Chaix ML, El Abbassi EM, Madelaine I, Katlama C, Valin N, Delobel P, Desseaux K, Peytavin G, Saillard J, Raffi F, Chevret S; ANRS 165 Darulight Study Group. Molina JM, et al. J Antimicrob Chemother. 2018 Aug 1;73(8):2129-2136. doi: 10.1093/jac/dky181. J Antimicrob Chemother. 2018. PMID: 29860402 Clinical Trial.